```html

Cutaneous Lupus Erythematosus (CLE)

Overview

Cutaneous Lupus Erythematosus (CLE) is an autoimmune disease in which the body’s immune system mistakenly attacks healthy skin cells, causing a variety of skin lesions. CLE can occur on its own (isolated cutaneous lupus) or alongside systemic lupus erythematosus (SLE), a condition that can affect the kidneys, joints, brain, and other organs.

• Who it affects: CLE most commonly appears in women between the ages of 20‑40, but men, children, and older adults can also develop it.
• Prevalence: Approximately 15‑20 % of all lupus patients have cutaneous involvement as the predominant manifestation. In the United States, an estimated 1.5 million adults have some form of lupus, giving a rough prevalence of CLE of about 150,000–300,000 people.<sup>[1][2]</sup>
• Types of CLE: The three major clinical subtypes are
  • Discoid Lupus Erythematosus (DLE) – chronic, scarring plaques.
  • Subacute Cutaneous Lupus Erythematosus (SCLE) – red, annular or papulosquamous lesions that usually do not scar.
  • Acute Cutaneous Lupus Erythematosus (ACLE) – typically a “butterfly” rash on the face that often accompanies systemic disease.

Symptoms

Skin findings vary by subtype, but common features include:

Discoid Lupus Erythematosus (DLE)

• Raised, coin‑shaped plaques with a thick, adherent scale (often described as “plugged hair follicles”).
• Scarring and pigment changes after the lesions heal, leading to permanent hair loss when scalp is involved.
• Location: scalp, ears, face, neck, and occasionally buttocks or arms.

Subacute Cutaneous Lupus Erythematosus (SCLE)

• Red, ring‑shaped (annular) or papulosquamous (psoriasis‑like) lesions.
• Minimal scarring but may cause temporary discoloration.
• Photosensitivity: lesions flare after sun exposure.
• Location: upper torso, shoulders, arms, and sometimes the face.

Acute Cutaneous Lupus Erythematosus (ACLE)

• Butterfly rash: symmetric erythema over the nasal bridge and cheeks.
• Other facial erythema (e.g., on the chin, ears, or scalp).
• Usually non‑scarring and resolves within weeks.
• Often indicates systemic involvement.

General skin‑related symptoms

• Itching (pruritus) or burning sensation.
• Pain or tenderness of lesions.
• Increased sensitivity to ultraviolet (UV) light (UV‑induced flares).
• Hair loss (alopecia) when scalp is affected.
• Systemic signs (fever, joint pain, fatigue) may appear if CLE is part of SLE.

Causes and Risk Factors

Like other autoimmune diseases, CLE results from a combination of genetic, hormonal, environmental, and immunologic factors.

Genetic predisposition

• Family history of lupus or other autoimmune disorders raises risk.
• Specific human leukocyte antigen (HLA) alleles—especially HLA‑DR2 and HLA‑DR3—are linked to CLE.<sup>[3]</sup>

Hormonal influence

• Estrogen may amplify immune activity, which helps explain the female predominance (about 9 women : 1 man).

Environmental triggers

• Ultraviolet radiation: Sunlight and tanning beds can provoke or worsen lesions.
• Medications: Certain drugs (e.g., terbinafine, procainamide, hydralazine) can induce a lupus‑like rash.
• Smoking: Strongly associated with SCLE and reduces response to therapy.<sup>[4]</sup>

Other risk factors

• Age 20‑45 (peak incidence).
• Higher prevalence in people of African, Asian, or Hispanic descent compared with non‑Hispanic whites.
• Concurrent autoimmune diseases such as Sjögren’s syndrome or rheumatoid arthritis.

Diagnosis

Diagnosing CLE involves a careful clinical exam, skin biopsy, and targeted laboratory testing.

Clinical evaluation

• Dermatologists assess lesion morphology, distribution, and photosensitivity.
• History focuses on sun exposure, medication use, and systemic symptoms.

Skin biopsy

A 4‑mm punch biopsy is taken from the edge of an active lesion.

• Histopathology: Interface dermatitis with vacuolar alteration of the basal layer, thickened basement membrane, and perivascular lymphocytic infiltrate.
• Direct immunofluorescence (DIF): Deposition of IgG, IgM, C3 at the dermo‑epidermal junction (“lupus band test”). Positive DIF supports the diagnosis.

Blood tests

• Antinuclear antibody (ANA): Positive in ~70 % of CLE patients; higher titers often suggest systemic disease.
• Anti‑Ro/SSA and anti‑La/SSB antibodies: Frequently seen in SCLE; presence predicts photosensitivity.
• Complete blood count, renal and liver panels to rule out systemic involvement.

Additional evaluations (if systemic lupus is suspected)

• Urinalysis for protein or blood.
• Complement levels (C3, C4) – low levels may indicate active systemic disease.
• Imaging (e.g., chest X‑ray) if lung involvement is a concern.

Treatment Options

Treatment aims to control skin inflammation, prevent scarring, and minimize systemic disease activity.

Topical therapies

• Corticosteroid creams or ointments (e.g., 0.05 % clobetasol) for short‑term flare control.
• Calcineurin inhibitors (tacrolimus 0.1 % ointment or pimecrolimus 1 %) are steroid‑sparing options, especially for delicate areas like the face.
• Retinoids (tazarotene) may be useful for hyperkeratotic lesions.

Systemic medications

• Antimalarials: Hydroxychloroquine (200‑400 mg/day) is first‑line for most CLE subtypes; it reduces lesions in 70‑80 % of patients.<sup>[5]</sup>
• Quinacrine can be added for hydroxychloroquine‑resistant disease.
• Systemic corticosteroids: Prednisone (≤10 mg/day) for severe flares; long‑term use is discouraged due to side effects.
• Immunosuppressants: Methotrexate, azathioprine, mycophenolate mofetil, or cyclosporine for refractory cases.
• Biologic agents: Belimumab (anti‑BAFF) and rituximab (anti‑CD20) have shown benefit in selected patients with systemic involvement.<sup>[6]</sup>

Procedural options

• Phototherapy (narrow‑band UVB): Paradoxically useful for some chronic lesions, but must be used under strict supervision because UV can trigger flares.
• Laser therapy: Fractional CO₂ laser can improve scarring after lesions have become inactive.

Lifestyle and supportive measures

• Sun protection: Broad‑spectrum SPF ≥ 50 sunscreen applied 15 minutes before exposure, re‑applied every 2 hours, and protective clothing.
• Smoking cessation: Improves response to antimalarials.
• Regular monitoring: Eye exams every 6‑12 months for hydroxychloroquine retinal toxicity.

Living with Cutaneous Lupus Erythematosus

Managing CLE is a daily commitment that blends medical treatment with practical self‑care.

Skin‑care routine

1. Gentle, fragrance‑free cleansers; avoid scrubbing.
2. Moisturize twice daily with emollients containing ceramides or hyaluronic acid.
3. Apply prescribed topical medication after cleansing and before moisturizers.

Sun‑safety habits

• Seek shade between 10 a.m. and 4 p.m.
• Wear UPF 50+ clothing, wide‑brim hats, and UV‑blocking sunglasses.
• Use sunscreen on all exposed skin, even on cloudy days.

Medication adherence

• Set daily alarms or use a pill‑box to avoid missed doses.
• Report new visual disturbances promptly (possible hydroxychloroquine toxicity).

Emotional well‑being

• Join support groups (e.g., Lupus Foundation of America, local dermatology clinics).
• Consider counseling if skin changes affect self‑esteem.
• Practice stress‑reduction techniques such as yoga, meditation, or deep‑breathing.

Regular follow‑up

Schedule dermatology visits every 3‑6 months, or sooner if lesions worsen. Annual labs (CBC, liver/kidney function, ANA, complement) help detect systemic activity early.

Prevention

While you cannot change genetic susceptibility, you can reduce flare‑inducing exposures.

• UV protection (as described above) is the most effective preventive measure.
• Avoid known trigger medications. Discuss any new drug with your rheumatologist or dermatologist.
• Quit smoking and limit alcohol, which can exacerbate skin lesions and interfere with medication metabolism.
• Maintain a healthy weight and balanced diet rich in antioxidants (fruits, vegetables, omega‑3 fatty acids) to support overall immune regulation.

Complications

If left untreated or poorly controlled, CLE can lead to several complications:

• Scarring and disfigurement: Permanent atrophic scars, especially from DLE, may cause cosmetic concerns and alopecia.
• Secondary infection: Crusted lesions can become colonized with bacteria or fungi.
• Progression to systemic lupus erythematosus: Up to 25 % of patients with SCLE develop systemic disease over 5 years.<sup>[7]</sup>
• Medication toxicity: Hydroxychloroquine can cause retinal damage; long‑term steroids increase risk of osteoporosis, diabetes, and hypertension.
• Psychosocial impact: Depression, anxiety, and reduced quality of life are common in chronic skin disease.

When to Seek Emergency Care

References

1. National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Lupus.” NIH, 2023.
2. Mayo Clinic. “Cutaneous lupus erythematosus.” Updated 2024.
3. Lee, E. S., et al. “HLA‑DR associations with cutaneous lupus.” *Arthritis & Rheumatology*, 2022.
4. U.S. Department of Health & Human Services, CDC. “Smoking and lupus.” 2023.
5. Feldman, B. M., & Tong, H. “Hydroxychloroquine in dermatology.” *Cleveland Clinic Journal of Medicine*, 2021.
6. Wang, J. et al. “Biologic therapy for refractory lupus.” *Journal of Clinical Immunology*, 2023.
7. Clifford, J., et al. “Progression from cutaneous to systemic lupus.” *Lupus Science & Medicine*, 2022.

```